Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates

International Immunopharmacology

Volumn 1, Issue 3, 2001, Pages 393-401

  Kraiczy, Peter ^a   Skerka, Christine ^b   Kirschfink, Michael ^c   Zipfel, Peter F ^b   Brade, Volker ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Borrelia burgdorferi; Complement; Factor H; FHL 1 reconectin; Immune evasion; Innate immunity; Lyme disease

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C6; COMPLEMENT FACTOR H; COMPLEMENT REGULATOR ACQUIRING SURFACE PROTEIN 1; COMPLEMENT REGULATOR ACQUIRING SURFACE PROTEIN 2; FIBRINOGEN; OUTER MEMBRANE PROTEIN; RECONECTIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

BACTERIOLYSIS; BACTERIUM ISOLATE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; BORRELIA INFECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; LYME DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; SPECIES DIFFERENCE;

BACTERIAL OUTER MEMBRANE PROTEINS; BORRELIA BURGDORFERI GROUP; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; LYME DISEASE;

EID: 0035095224     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(00)00041-2     Document Type: Conference Paper

References (55)

1. Epidemiology of European Lyme borreliosis
2. Centers for Disease Control and Prevention, Lyme - United States, 1996
3. Lyme disease - A tick borne spirochetosis?
4. Lyme disease
5. Characteristics of the pathogen
6. Molecular typing of Borrelia burgdorferi sensu lato: Taxonomic, epidemiological, and clinical implications
7. Innate immune recognition: Mechanisms and pathways
8. Complement evasion by bacteria and parasites
9. The alternative pathway: Activation and regulation
10. Complement evasion strategies of microorganism
11. Target recognition failure by the nonspecific defense system: Surface constituents of pathogens interfere with the alternative pathway of complement activation
12. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry
13. Human complement regulators: A major target for pathogenic microorganisms
14. Identification of a domain in human factor H and factor H-like protein-1 required for the interaction with streptococcal M proteins
15. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H
16. A novel sialic acid binding site on factor H mediates serum resistance of sialyted Neisseria gonorrhoeae
17. Binding of complement factor H to loop 5 of porin protein 1A: A molecular mechanisms of serum resistance of nonsialyted Neisseria gonorrhoeae
18. The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis
19. Complement evasion by Echinococcus granulosus: Sequestration of host factor H in the hydatid cyst wall
20. Role of Yad A protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules
21. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)
22. FHL-1/reconectin and factor H: Two human complement regulators which are encoded by the same gene are differently expressed and regulated
23. The factor H protein family
24. Factor H and disease: A complement regulator affects vital body functions
25. FHL-1/reconectin: A human complement and immune regulator with cell-adhesive function
26. Identification of complement regulatory domains in human factor H
27. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H
28. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H
29. Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway
30. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi
31. Facilitation of complement-dependent killing of the Lyme disease spirochete, Borrelia burgdorferi, by specific immunoglobulin G Fab antibody fragments
32. Difference of two Borrelia burgdorferi strains in complement activation and serum resistance
33. Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi
34. Comparison of two laboratory methods for the determination of serum resistance in Borrelia burgdorferi isolates
35. Complement-mediated serum sensitivity among spirochetes that cause Lyme disease
36. Growth inhibitory and bactericidal efficacy of sera from Lyme borreliosis patients on B. burgdorferi strains
37. Serum complement sensitivity as a key factor in Lyme disease ecology
38. Mannose-binding lectin: The pluripotent molecule of the innate immune system
39. Complement resistance in Borrelia burgdorferi strain 297: Outer membrane protein prevent MAC formation at lysis susceptible sites
40. Borrelia burgdorferi mutant lacking Osp: Biological and immunological characterization
41. Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant
42. Complement-resistance strains of Borrelia burgdorferi exhibit a 90-kDa protein with antigenic similarities with human CD59
43. Antiphagocytic activity of streptococcal M protein: Selective binding of complement control protein factor H
44. Role of the hypervariable region in streptococcal M proteins: Binding of a human complement inhibitor
45. Assessment of the interaction of human complement regulatory proteins with group A streptococcus: Identification of a high affinity group A streptococcus binding site in FHL-1
46. The control of homologous lysis
47. Membrane proteins that protect against complement lysis
48. Complement C3 convertase: Cell surface restriction of beta1H control and generation of restriction on neuramidase-treated cells
49. Localization of the complement component C3b binding site and the cofactor activity for factor I in the 38 kDa tryptic fragment of factor H
50. Human complement C3b inactivator: Isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution
51. Each of the three binding sites on factor H interacts with a distinct site on C3b
52. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: Evidence for multiple interactions between H and surface bound C3b
53. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis